Peripheral Vertigo (BPPV-Refractory / Vestibular Neuritis Recovery)
Investigational adjunct for peripheral vertigo persisting after Epley maneuvers or during prolonged vestibular neuritis recovery; anecdotal.
Patienten-Zusammenfassung
- Ist dies FDA-zugelassen fuer diese Anwendung?
- Not FDA-cleared for refractory peripheral vertigo / vestibular neuritis recovery. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- Welche Evidenz existiert?
- Tier C (investigational). No controlled trials. Evidence-based first-line management of BPPV is canalith repositioning maneuvers (Epley, Semont) which resolve 80-90% of cases in 1-3 sessions; for vestibular neuritis the standard is short-course steroids in the acute phase plus vestibular rehabilitation. Leeches should only be considered after these have been adequately tried.
- Hauptrisiken
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Transient worsening of dizziness during and shortly after sessions
- Wer dies nicht in Betracht ziehen sollte
- Patients whose BPPV has not been adequately treated with at least 2-3 Epley or Semont maneuvers by a vestibular specialist
- Patients with central vertigo (cerebellar stroke, demyelinating disease) — leeches will not help and may delay diagnosis
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
- People with hemophilia or any other inherited bleeding disorder
- Patients with severe anemia (hemoglobin under 10 g/dL)
- People with an active infection at the planned application site
- Patients who are pregnant or breastfeeding (relative contraindication; insufficient safety data)
- Was Sie Ihren Kliniker fragen sollten
- Has my vertigo been evaluated by a vestibular specialist to confirm it is peripheral and not central?
- Have I had a proper trial of Epley or Semont maneuvers (the standard BPPV treatment)?
- Could my symptoms be better explained by another vestibular condition that has a specific evidence-based treatment?
- What is the published evidence base for leech therapy in this condition?
- How will improvement be measured objectively, not just by my report?
- Will leeches interfere with vestibular rehabilitation exercises?
- Wann dringende medizinische Versorgung suchen
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Sudden severe headache, double vision, slurred speech, facial droop, or arm or leg weakness (possible stroke)
- Inability to walk or sit up because of dizziness lasting more than a few hours
Was dies NICHT bedeutet
- It does not mean leech therapy is FDA-cleared for vertigo — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace canalith repositioning maneuvers, which are the proven first-line treatment for BPPV.
- It does not work for central causes of vertigo, which require neurology rather than ENT attention.
- It does not have controlled-trial evidence for any vertigo subtype.
- It does not accelerate vestibular compensation beyond what targeted rehabilitation already provides.
Sicherheits-Querverweise
Clinical Profile
- Category
- ent
- ICD-10
- H81.10, H81.11, H81.12, H81.13, H81.20, H81.23
- Safety tier
- medium
Evidence Summary
Peripheral vertigo encompasses BPPV (usually resolved by canalith repositioning), vestibular neuritis, and labyrinthitis. Leech therapy has no evidence base in BPPV — particle repositioning maneuvers (Epley, Semont) remain first-line, and no controlled trial or published case series of leech therapy for peripheral vertigo exists. Any adjunctive use in prolonged vestibular recovery via mastoid placement is purely anecdotal and investigational. Use is highly experimental; vestibular rehabilitation therapy remains the evidence-based mainstay.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Ahmed S et al. (2020)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Central vertigo (must rule out with MRI brain)
- Active middle ear infection
- Unstable balance with high fall risk
Related Conditions
Chronic Rhinosinusitis
Off-label use with one RCT showing symptom and SNOT-22 score improvement at 4 weeks in non-polypoid chronic sinusitis.
Subjective Tinnitus
Investigational use for chronic subjective tinnitus; case-series evidence for THI score improvement. Mechanism speculative.
Ménière's Disease (Adjunctive)
Investigational adjunctive use for Ménière's disease; very limited evidence. Standard management (diet, betahistine, intratympanic therapy) remains primary.
Pulsatile Tinnitus (Vascular-Origin Subtype)
Investigational use for pulsatile vascular-origin tinnitus distinct from subjective tinnitus; case-report evidence only.